Background/Aims: The aim of the present study was to investigate whether short children with normal growth hormone (GH) immunoreactivity, but reduced bioactivity (bio-inactive GH) could benefit from rhGH treatment as GH deficient (GHD) patients. Methods:We evaluated 12 pre-pubertal children (8 M, 4 F), with GH deficiency-like phenotype showing normal serum GH peak levels > 10 ng/ml), measured by immunofluorimetric assay (IFMA-GH), in contrast with a reduced GH bioactivity (bio-GH), evaluated using the Nb-2 cells. We also evaluated 15 age-matched GHD pre-pubertal children (11 M, 4 F) with serum GH peak < 5 ng/ml. Both groups were treated with rhGH therapy at the dose of 0.23 mg/kg/week s.c. Results: Serum bio-GH/IFMA-GH ratio at peaktime for each patient during the provocative test was significantly lower in bioinactive GH than in GHID children (0.29 vs. 2.05, p = 0.00001). Recombinant human GH therapy induced a significant (p < 0.001) increase in growth rate in both groups during the first 2 years. In the third year of treatment, while growth rate in GHD children is maintained, in bioinactive GH patients it decreases remaining, however higher compared to the pre-treatment one. Conclusions: Short rhGH therapy given to selected bioinactive GH children improve growth rate and might result in greater final adult height. Copyright (c) 2006 S. Karger AG, Basel.

Response to Long-Term Growth Hormone Therapy in Short Children with Reduced GH Bioactivity / Travaglino, P; Buzi, F; Meazza, C; Pagani, S; Tinelli, C; Iughetti, Lorenzo; De Sanctis, V; Aimaretti, G; Poddighe, D; Barberi, S; Bozzola, M.. - In: HORMONE RESEARCH. - ISSN 0301-0163. - STAMPA. - 66:(2006), pp. 189-194.

Response to Long-Term Growth Hormone Therapy in Short Children with Reduced GH Bioactivity.

IUGHETTI, Lorenzo;
2006-01-01

Abstract

Background/Aims: The aim of the present study was to investigate whether short children with normal growth hormone (GH) immunoreactivity, but reduced bioactivity (bio-inactive GH) could benefit from rhGH treatment as GH deficient (GHD) patients. Methods:We evaluated 12 pre-pubertal children (8 M, 4 F), with GH deficiency-like phenotype showing normal serum GH peak levels > 10 ng/ml), measured by immunofluorimetric assay (IFMA-GH), in contrast with a reduced GH bioactivity (bio-GH), evaluated using the Nb-2 cells. We also evaluated 15 age-matched GHD pre-pubertal children (11 M, 4 F) with serum GH peak < 5 ng/ml. Both groups were treated with rhGH therapy at the dose of 0.23 mg/kg/week s.c. Results: Serum bio-GH/IFMA-GH ratio at peaktime for each patient during the provocative test was significantly lower in bioinactive GH than in GHID children (0.29 vs. 2.05, p = 0.00001). Recombinant human GH therapy induced a significant (p < 0.001) increase in growth rate in both groups during the first 2 years. In the third year of treatment, while growth rate in GHD children is maintained, in bioinactive GH patients it decreases remaining, however higher compared to the pre-treatment one. Conclusions: Short rhGH therapy given to selected bioinactive GH children improve growth rate and might result in greater final adult height. Copyright (c) 2006 S. Karger AG, Basel.
66
189
194
Response to Long-Term Growth Hormone Therapy in Short Children with Reduced GH Bioactivity / Travaglino, P; Buzi, F; Meazza, C; Pagani, S; Tinelli, C; Iughetti, Lorenzo; De Sanctis, V; Aimaretti, G; Poddighe, D; Barberi, S; Bozzola, M.. - In: HORMONE RESEARCH. - ISSN 0301-0163. - STAMPA. - 66:(2006), pp. 189-194.
Travaglino, P; Buzi, F; Meazza, C; Pagani, S; Tinelli, C; Iughetti, Lorenzo; De Sanctis, V; Aimaretti, G; Poddighe, D; Barberi, S; Bozzola, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/612116
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact